Summary
The PARTNER II trial investigated the use of the SAPIEN 3 transcatheter aortic valve replacement in patients who were high-risk/inoperable or intermediate-risk for surgical complications. Clinical outcomes were excellent, with low rates of adverse events and paravalvular leak.
- aortic stenosis
- transcatheter heart valve
- SAPIEN 3
- transcatheter aortic valve replacement
- stroke
- mortality
- paravalvular leak
- cardiology & cardiovascular medicine clinical trials
- NCT01314313
- © 2015 SAGE Publications
Tools
SAPIEN 3 TAVR System Produces Excellent Clinical Outcomes in PARTNER II Trial
Permalink:
Table of contents
Cited By...
- No citing articles found.